MEDIA RELEASE
MEDIA RELEASE
FOR IMMEDIATE RELEASE
ACE Welcomes New PBS Listings for Contraception, Endometriosis, and IVF: A Win for the Community
16 March 2925
The Endometriosis Coalition (ACE) welcomes the new and amended Pharmaceutical Benefits Scheme (PBS) listings, which will provide greater access to affordable contraception, endometriosis treatment, and IVF for Australians.
These listings are a direct response to the voices of our community. For years, people living with endometriosis and pelvic pain and doctors have called for more affordable treatment options, and today’s announcement is a significant step forward.
From May 1:
✅ Slinda® (Drospirenone), a progestogen-only contraceptive pill, will be listed on the PBS for the first time—making it a more affordable option for those who cannot take estrogen-based contraceptives. Over 100,000 Australians per year are expected to benefit from this listing, cutting costs from $250+ per year to a PBS co-payment.
✅ Ryeqo® (Relugolix with estradiol and norethisterone acetate), a endometriosis symptom treatment for those experiencing symptoms of moderate to severe pain, will be added to the PBS. Without subsidy, Ryeqo could cost over $2,700 per year—now, it will be significantly more accessible.
From April 1:
✅ Pergoveris® (Follitropin alfa with Lutropin alfa), used in IVF treatment, will be funded earlier in the IVF cycle, removing financial barriers and improving access for those struggling with infertility. The maximum number of Pergoveris pens per script will also double, reducing out-of-pocket costs by thousands of dollars per cycle.
A Win for Endometriosis Advocacy
“These additional PBS listings are a direct result of years of advocacy and the voices of those with lived experience,” said Ms Taylor, Chair of the Endometriosis Coalition.
“For too long, people with endometriosis have faced financial and systemic barriers to accessing the treatments they need. This is a step in the right direction, but there is still more to be done. We will continue to push for greater recognition, better treatments, and long-term investment in research and care.”
This announcement follows the Australian Government’s historic $573.3 million investment in women’s+ health, demonstrating an ongoing commitment to improving healthcare equity.
ACE remains committed to advocating for accessible, evidence-based care and ensuring that all Australians living with endometriosis and pelvic pain can access the treatments they need without financial hardship.
Media Contact:
Jess Taylor, Chair, Endometriosis Coalition
Email: info@acendo.com.au
Phone: 0434106341
About the Endometriosis Coalition
The Endometriosis Coalition is Australia’s peak body for endometriosis and pelvic pain, representing patients, healthcare professionals, researchers, and advocacy organisation’s. The Coalition drives national collaboration, policy change, and research investment to improve diagnosis, treatment, and support for the 1 in 7 Australians living with endometriosis and pelvic pain. Through partnerships with health professionals, government, and community organisations, the Endometriosis Coalition empowers those affected and works toward systemic change.